Biotechnology

Alkeus Pharmaceuticals will present crucial data on its oral drug for Stargardt disease, a leading cause of juvenile blindness with no current cure.

With fresh capital, the Swedish biotech is scaling its revolutionary platform that decodes cellular communication, fueling a major US expansion.

A Boston biotech is using AI and targeted mRNA to program cells inside the body, aiming to make complex CAR T treatments safer and universally accessible.

As life-saving gene therapies face billion-dollar payment hurdles, a key appointment signals a strategic shift from scientific breakthrough to market access.

New pre-clinical data shows engineered immune cells (iMacrophages) can effectively target and destroy ovarian tumors, offering hope for a new treatment era.

Biotech firm Scribe Therapeutics, co-founded by a Nobel laureate, is pioneering a new gene therapy for high cholesterol that silences genes, not cuts them.

South Korea approves its first homegrown CAR-T therapy, a landmark achievement offering new hope for lymphoma patients with impressive response rates.

New at-home tests for IBS and SIBO are gaining validation, promising faster diagnoses and revealing surprising links between gut health and systemic diseases.

With $5M in new funding and key regulatory validation, Sapho Bio's rapid sterility test promises to slash drug release times and speed medicines to patients.

The clinical trial leader renewed a key global certification, signaling a new era of quality and trust that could accelerate breakthroughs in Alzheimer's.

A new AI platform, SAVA, launched by EverythingALS, promises to connect ALS patients with clinical trials, tackling a major barrier in the search for a cure.

A novel immunotherapy that freezes and infuses tumors shows an 87% response rate in advanced prostate cancer, aiming to turn local treatment into a systemic attack.

As AI accelerates drug approvals, a new bottleneck emerges. Firms like Totaligent are betting on the infrastructure needed to get therapies to patients.

Swedish firm Navinci launches its Omni kit, targeting the spatial interactomics market with a new tool to visualize protein networks directly in tissue.

TRexBio has dosed the first patient in a new trial for its novel drug, TRB-061, which aims to rebalance the immune system to treat atopic dermatitis.

As RNA therapies boom, a new enzymatic platform promises to solve critical manufacturing bottlenecks, making next-gen drugs more scalable and sustainable.

Imviva Biotech's new CAR-T therapy shows potential for durable remission in lupus, moving advanced cell treatments beyond cancer to autoimmune disease.

Berlin-based Tacalyx is advancing its lead drug, TCX-201, to the clinic, targeting a novel class of antigens once thought impossible to drug.

A new stem cell therapy promises a one-time cure for hemophilia A, and the FDA is clearing the path. Could lifelong, costly infusions become a memory?

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.